Clinical Trial Update: Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation [Phase 1]

View source ↗

Summary

Phase I study of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation; the trial is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• HRS-4642

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced KRAS G12D Mutant Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING